Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting

Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting

SALT LAKE CITY, Oct. 08, 2019 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that it will present results from five studies at the 2019 American Society of Human Genetics (ASHG) annual meeting being held Oct. 15–19, 2019 in Houston, TX.

“We are excited to present multiple studies at this year’s ASHG meeting,” said James Goldberg, M.D., board certified maternal fetal medicine specialist, medical geneticist and chief medical officer, Myriad Women’s Health. “We continue our commitment to advancing the science of genetic testing and delivering on the promise of precision medicine.”

A list of presentations at 2019 ASHG are below.  Follow Myriad on Twitter via @myriadgenetics and keep up to date with ASHG meeting news and updates by using the hashtag #ASHG19.

Featured Research at 2019 ASHG
Myriad
Product
 Abstract  Author  Poster Details
myRisk®
Hereditary
Cancer
 
Common potential pathogenic variants in PMS2CL that can present in PMS2 with extremely low frequencies Shujuan
Pan
Poster (2424W )
Wednesday, Oct. 16, 2019
3:00-4:00 p.m.
Exhibit Hall, Level 1
Functional classification of selected exonic splicing variants occurring outside of canonical 5’ and 3’ exon boundaries in cancer-predisposing genes Paola
Nix
Poster (898T)
Thursday, Oct. 17, 2019
3:00-4:00 p.m.
Exhibit Hall, Level 1
 
Foresight®
Carrier
Screen
 
Leveraging large datasets accumulated through population carrier screening to inform variant classification David
Tran
Poster (1575W)
Wednesday, Oct. 16, 2019
2:00-3:00 p.m.
Exhibit Hall, Level 1
Accurate and high-resolution copy number variant detection in clinical germline screening Jiani
Li
Poster (1653W)
Wednesday, Oct. 16, 2019
2:00-3:00 p.m.
Exhibit Hall, Level 1
A deep learning model for accurate variant calling in congenital adrenal hyperplasia Sun
Hong
Poster (1410W)
Wednesday, Oct. 16, 2019
3:00-4:00 p.m.
Exhibit Hall, Level 1
 

About Myriad myRisk® Hereditary Cancer
The Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.

About Foresight® Carrier Screen
The Myriad Foresight Carrier Screen is designed to maximize detection of at-risk couples for serious, prevalent, and clinically-actionable conditions. Foresight has a rigorous disease selection that focuses on 175+ conditions that provides meaningful information to patients. Additionally, Foresight offers superior technology with unmatched detection rates for the vast majority of genes on the panel (>99% across ethnicities) which means patients can trust both positive and negative results.

About Myriad Genetics
Myriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on five critical success factors:  building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020.  For more information on how Myriad is making a difference, please visit the Company’s website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

https://www.globenewswire.com/

Share this:
October 11, 2019 / Pharma News